News
Reverse Remodeling of LV in Patients with Diabetes/Prediabetes and Heart Failure with Reduced Ejection Fraction Treated with Empagliflozin
Authors of the British study SUGAR-DM-HF published in February 2021 examined whether empagliflozin reduces left ventricle (LV) volume in patients with type 2 diabetes mellitus (DM), prediabetes, and heart failure with reduced ejection fraction (EF). This favorable reverse remodeling of the LV could be a mechanism through which empagliflozin achieves reduced hospitalization rates for heart failure and overall mortality in these patients.
Current Status in the Issue of Alpha-1-Antitrypsin Deficiency
Material by Italian and Swiss authors published in the European Respiratory Review details current…
Mental Health During the Pandemic − and How to Alleviate Its Impacts
At the symposium during the XV Spring Interactive Conference of the General Medical Society of ČLS…
Stabilization of Liver Metastases of CRC with Trifluridine/Tipiracil in 3rd Line Therapy – Case Study
We present a case study of a man born in 1944 who underwent resection of the rectosigmoid for…
Levodropropizine – a non-codeine antitussive with minimal side effects, contraindications, and drug interactions
For symptomatic treatment of dry, irritating, and exhausting cough, both codeine and non-codeine…
From Hell to the Light at the End of the Tunnel – A Task for Eletriptan
In recent months, under the spotlight of new biological treatments, the focus has been…
Brentuximab Vedotin as Another Therapeutic Option in Cutaneous T-Cell Lymphoma
Current systemic treatment for patients with cutaneous T-cell lymphoma (CTCL) unfortunately has…
Current Recommendations of the Expert Panel on the Management of von Willebrand Disease
Von Willebrand disease (vWD) is a common congenital bleeding disorder. The care of patients with…
How and with What the National Registry of Primary Immunodeficiencies Benefits Specialists and Patients
Primary immunodeficiencies constitute a very heterogeneous group of congenital diseases. They…
Update of the Blue Book: What's New in the Treatment of Metastatic NSCLC with an ALK Gene Mutation?
As of March 1, 2022, the 28th update of the Blue Book by the Czech Society for Oncology of ČLS JEP…
Conferences
News from the world of medicine
All conferences
Popular this week
- Multiple system atrophy
- Intermittent Fasting May Carry Significant Health Risks
- How Compassion Fatigue Threatens Doctors and Other Healthcare Workers
- Tuberous Sclerosis
- A device the size of a matchbox will help treat obstructive sleep apnea